Abstracts Archive - Page 2144 of 2425 - ACR Meeting Abstracts

Abstract Number: 1617 • 2013 ACR/ARHP Annual Meeting
Toll-Like Receptor 3 Plays a Role In Loss Of Tolerance To The Ro/SSA Auto-Antigen In Systemic Lupus Erythematosus
Julie Ducreux¹, Christine Galant², Julie Verbeeck², Pierre Coulie³, Benoît Van den Eynde³, Frédéric A. Houssiau¹ and Bernard Lauwerys², ¹Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ²Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ³Institut de Duve, Université catholique de Louvain, Brussels, Belgium
Background/Purpose: Toll-like Receptor (TLR)7 and TLR9 play a role in the pathogenesis of systemic lupus erythematosus (SLE) by inducing Interferon (IFN)-α and IFN-induced genes expression.…
Abstract Number: 1618 • 2013 ACR/ARHP Annual Meeting
Chromatin Binding In SLE Patients Correlates With The Intensity Of Apoptotic Binding By 9G4+ B Cells
Asiya Seema Chida¹, Quan-Zhen Li², Chandra Mohan³, Youliang Wang¹, Scott Jenks⁴, Louise Hartson¹ and Ignacio Sanz⁵, ¹Medicine, Emory University Medical Center, Atlanta, GA, ²Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ³University of Houston, Houston, TX, ⁴Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁵Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-organ autoimmune disease characterised by production of autoantibodies to multiple nuclear antigens, some of which are highly specific…
Abstract Number: 1619 • 2013 ACR/ARHP Annual Meeting
In Vitro Assessments Of Mesenchymal Stem Cells From Lupus Patients To Predict Suppressive Function In Vivo
Erin Collins¹, Fei Gu² and Gary S. Gilkeson³, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology,Medical University of South Carolina, Charleston, SC, ³Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Broad immune suppression by mesenchymal stem cells (MSCs) make them an attractive candidate as a cell therapy for autoimmune diseases, such as systemic lupus…
Abstract Number: 1620 • 2013 ACR/ARHP Annual Meeting
Characterization Of a Jamaican Lupus Cohort: Proinflammatory Biomarkers and Disease Activity
Rohan Willis¹, Monica Smikle², Karel de Ceulaer³ and Silvia S. Pierangeli⁴, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Microbiology, University of the West Indies, Kgn 7, Jamaica, ³Microbiology, University of the West Indies, KIngston, Jamaica, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are related systemic autoimmune diseases associated with proinflammatory prothrombotic biomarkers/cytokine (PPM) and antiphospholipid antibodies (aPL). Reports…
Abstract Number: 1621 • 2013 ACR/ARHP Annual Meeting
T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Odilia B.J. Corneth¹, Zana Brkic², Cornelia G. van Helden-Meeuwsen³, Radboud J.E.M. Dolhain⁴, Naomi I. Maria³, Sandra M.J. Paulissen⁴, Nadine Davelaar⁵, Jan Piet van Hamburg⁵, Paul L. Van Daele³, Virgil A. Dalm², Martin van Hagen³, Marjan A. Versnel² and Erik Lubberts⁶, ¹Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: A hallmark of systemic autoimmune diseases, such as systemic lupus erythematotsus (SLE), is the increased expression of interferon (IFN) type I inducible genes, the…
Abstract Number: 1622 • 2013 ACR/ARHP Annual Meeting
Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis
Beatrice Goilav¹, Iddo Z. Ben-Dov², Irene Blanco³, Olivier Loudig⁴, Dawn M. Wahezi⁵ and Chaim Putterman⁶, ¹Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ²Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Epidemiology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN), particularly, ISN/RPS class IV LN, is associated with significant morbidity and mortality. microRNAs (miRs) are small, non-coding RNAs that regulate translation.…
Abstract Number: 1582 • 2013 ACR/ARHP Annual Meeting
The Accrual Of Damage In Corticosteroid-Naïve Patients With Systemic Lupus Erythematosus
Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite improved survival rates in systemic lupus erythematosus (SLE) over the last 4 decades, organ damage and associated morbidity continues over time. Corticosteroids (CS)…
Abstract Number: 1597 • 2013 ACR/ARHP Annual Meeting
Autonomic Dysfunction In Systemic Lupus Erythematosus Patients With Previous Neuropsychiatric Involvement
Yang Gao, Sheung Wei Li, Lai Heung Chau, Chak Sing Lau and Mo Yin Mok, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Autonomic dysfunction has increasingly been described to be associated with central nervous system (CNS) disorders and has been attributed to damage of the central…
Abstract Number: 1583 • 2013 ACR/ARHP Annual Meeting
Serositis In Systemic Lupus Erythematosus: Prevalence, Recurrence, Treatment and Outcome
Mansour Somaily¹, Dafna D. Gladman², Dominique Ibanez² and Murray B. Urowitz², ¹Medicine, Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Serositis is one of the ACR classification criteria for SLE. Its incidence is variable in studies varying from 12 to 60%. The aim of…
Abstract Number: 1584 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Chronic Isolated Thrombocytopenia In Patients With Systemic Lupus Erythematosus
Amanda J. Steiman¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Past studies have revealed disparity in the clinical significance of thrombocytopenia in systemic lupus erythematosus (SLE), ranging from a benign and incidental finding in…
Abstract Number: 1585 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Daniel J. Wallace³, David Roth⁴, Charles T. Molta⁴, Anne Hammer⁵, Tom Tang⁵ and April Thompson⁵, ¹The Karolinska Institute, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, King of Prussia, PA, ⁵GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently receive corticosteroids (CS) as standard therapy. We examined the effects of belimumab on CS dose across 52…
Abstract Number: 1586 • 2013 ACR/ARHP Annual Meeting
Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Elisabeth M.A Ball¹, Arthur Grey², Ai Lyn Tan³, Eiji Fukuba⁴, Gunter Steiner⁵, Dennis McGonagle⁶, Aubrey Bell⁷ and Madeleine Rooney⁸, ¹Rheumatology, Queens' University/Musgrave Park Hospital, Belfast, United Kingdom, ²Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Radiology, Shimane University, Izuma, Japan, ⁵Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Rheumatology Unit, Musgrave Park Hospital, Belfast, United Kingdom, ⁸Medicine, Queens University Belfast, Belfast, United Kingdom
Background/Purpose: Musculoskeletal involvement in systemic lupus erythematosus (SLE) is common but poorly characterised with only a few Magnetic Resonance Imaging (MRI) or ultrasound (US) studies…
Abstract Number: 1587 • 2013 ACR/ARHP Annual Meeting
Continuous Variables Of Treatment Interventions In Patients Diagnosed With Systemic Lupus Erythematosus Among Commercially and Medicaid Insured Populations In The U.S
Hong Kan¹, Saurabh Nagar¹, Jeetvan Patel¹, Anna Oh², Daniel J. Wallace³ and Charles T. Molta⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²University of California San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, joints, and the nervous system. Standard…
Abstract Number: 1588 • 2013 ACR/ARHP Annual Meeting
Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Jun Liu², Graciela S. Alarcon³, Karen H. Costenbader⁴ and Candace H. Feldman⁵, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, Boston, CA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with systemic lupus erythematosus (SLE) and have been shown to improve outcomes,…
Abstract Number: 1589 • 2013 ACR/ARHP Annual Meeting
Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus
Patricia P. Katz¹, Chris Tonner¹, Laura Trupin¹, Edward H. Yelin² and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA
Background/Purpose: Depression is commonly reported in systemic lupus erythematosus (SLE), yet information is lacking about long-term patterns of depression. In particular, because depression is thought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].